Clinical Trials · NCT04943068
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
- Enrollment
- 193
- Start date
- May 2021
- Locations
- 1 site, South Korea
- Primary endpoint
- Change from baseline to End of Study in the desire domain from the FSFI